Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43233   clinical trials with a EudraCT protocol, of which   7153   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-004588-11
    Sponsor's Protocol Code Number:ABR64005
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2019-09-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2017-004588-11
    A.3Full title of the trial
    Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease.
    Veilige controle van de ziekte van Crohn trial: Lang termijn effectiviteit en veiligheid van periodieke behandeling met adalimumab versus standaard step-up behandeling van nieuwe patiënten met de ziekte van Crohn.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment.
    Veilige controle van de ziekte van Crohn trial: Lang termijn effectiviteit en veiligheid van 6 maanden behandeling met adalimumab versus standaard step-up behandeling van nieuwe patiënten met de ziekte van Crohn.
    A.3.2Name or abbreviated title of the trial where available
    CoCroS trial
    CoCros studie
    A.4.1Sponsor's protocol code numberABR64005
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMaastricht University Medical Centre
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportZonMW
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMUMC+
    B.5.2Functional name of contact pointDivision Gastroenterology Hepatolog
    B.5.3 Address:
    B.5.3.1Street AddressDebeyelaan 25
    B.5.3.2Town/ cityMaastricht
    B.5.3.3Post code6202 Az
    B.5.3.4CountryNetherlands
    B.5.6E-mailm.pierik@mumc.nl
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Humira
    D.2.1.1.2Name of the Marketing Authorisation holderAbbvie
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Suspension for injection in pre-filled pen
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    The Chronic inflammatory bowel disease Crohn's disease
    De chronische inflammatoire darmaandoening de ziekte van Crohn
    E.1.1.1Medical condition in easily understood language
    Chronic inflammatory disease of he bowel Crohn's disease
    De chronische darmontsteking de ziekte van Crohn
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The aim of this study is to compare the long-term efficacy and safety of standard step-care with corticosteroid/budesonide as the initial treatment, with step-care with adalimumab as initial treatment for newly diagnosed CD patients.
    Primary outcome
    Quartiles of clinical and biochemical disease remission at week 96
    The aim of this study is to compare the long-term efficacy and safety of standard step-care with corticosteroid/budesonide as the initial treatment, with step-care with adalimumab as initial treatment for newly diagnosed CD patients
    Primary outcome
    Quartiles of clinical and biochemical disease remission at week 96
    E.2.2Secondary objectives of the trial
    Safety outcome
    Disease progression at week 96 on MRI-enterography
    Drug related serious adverse events
    Serious disease related adverse events (hospitalisation, surgery)

    Secondary outcomes
    Total health care costs at week 96
    Cumulative corticosteroid dose at week 24, 48 and 96
    Proportion of endoscopic remission at week w24
    time to remission
    PROM: quality of life week 24, 48 and 96
    PROM: (work) disability week 24, 48 and 96
    PROM: tolerability of treatment week 24, 48 and 96
    Safety outcome
    Disease progression at week 96 on MRI-enterography
    Drug related serious adverse events
    Serious disease related adverse events (hospitalisation, surgery)

    Secondary outcomes
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Newly diagnosed treatment naive CD patients or patients with an established diagnosis without medical treatment for > 1 year and naïve to biologicals or thiopurines visiting the outpatient clinic or endoscopy ward of the participating centres.
    • CD diagnosis according to ECCO-guidelines + complete ileo-colonoscopy + complete small bowel imaging at diagnosis (MRI or CT-enterography)
    • Sufficient knowledge Dutch language
    • 18 years old < 65 years old
    • No-contraindication for anti-TNF or immunosuppressant treatment. (Contra-indications are: a symptomatic stricture, an abscess, a history of tuberculosis or other granulomatous infection, a positive chest radiograph or Quantiferon or tuberculin skin test with purified protein derivative, a recent history of an opportunistic infection (within the previous 6 months), active infection with hepatitis B or C, infection with the human immunodeficiency virus, multiple sclerosis, cancer(except adequately treated non melanoma skin cancer), or a homozygous mutant or heterozygous thiopurine methyltransferase phenotype).
    • No contra-indication for MRI-enterography
    • Smartphone or tabloid with internet access
    • Newly diagnosed treatment naive CD patients or patients with an established diagnosis without medical treatment for > 1 year and naïve to biologicals or thiopurines visiting the outpatient clinic or endoscopy ward of the participating centres.
    • CD diagnosis according to ECCO-guidelines + complete ileo-colonoscopy + complete small bowel imaging at diagnosis (MRI or CT-enterography)
    • Sufficient knowledge Dutch language
    • 18 years old < 65 years old
    • No-contraindication for anti-TNF or immunosuppressant treatment. (Contra-indications are: a symptomatic stricture, an abscess, a history of tuberculosis or other granulomatous infection, a positive chest radiograph or Quantiferon or tuberculin skin test with purified protein derivative, a recent history of an opportunistic infection (within the previous 6 months), active infection with hepatitis B or C, infection with the human immunodeficiency virus, multiple sclerosis, cancer(except adequately treated non melanoma skin cancer), or a homozygous mutant or heterozygous thiopurine methyltransferase phenotype).
    • No contra-indication for MRI-enterography
    • Smartphone or tabloid with internet access
    E.4Principal exclusion criteria
    A potential subject who meets any of the following criteria will be excluded from participation in this study:
    • Malignancy in 5 years before treatment. Exception adequate treated non-melanoma skin cancer
    • Perianal fistula at diagnosis
    • Sever disease requiring hospitalisation at diagnosis
    • Contra-indication for anti-TNF or immunosuppressive
    Patients with the short bowel syndrome or an ostomy
    A potential subject who meets any of the following criteria will be excluded from participation in this study:
    • Malignancy in 5 years before treatment. Exception adequate treated non-melanoma skin cancer
    • Perianal fistula at diagnosis
    • Sever disease requiring hospitalisation at diagnosis
    • Contra-indication for anti-TNF or immunosuppressive
    Patients with the short bowel syndrome or an ostomy
    E.5 End points
    E.5.1Primary end point(s)
    Quartiles of clinical and biochemical disease remission at week 96
    Kwartalen prednison vrije klinische en biochemische remissie op
    E.5.1.1Timepoint(s) of evaluation of this end point
    week 96
    week 96
    E.5.2Secondary end point(s)
    Safety outcome
    Disease progression at week 96 on MRI-enterography
    Drug related serious adverse events
    Serious disease related adverse events (hospitalisation, surgery)

    Secondary outcomes
    Total health care costs at week 96
    Cumulative corticosteroid dose at week 24, 48 and 96
    Proportion of endoscopic remission at week w24
    time to remission
    PROM: quality of life week 24, 48 and 96
    PROM: (work) disability week 24, 48 and 96
    PROM: tolerability of treatment week 24, 48 and 96
    Safety outcome
    Disease progression at week 96 on MRI-enterography
    Drug related serious adverse events
    Serious disease related adverse events (hospitalisation, surgery)

    Secondary outcomes
    Total health care costs at week 96
    Cumulative corticosteroid dose at week 24, 48 and 96
    Proportion of endoscopic remission at week w24
    time to remission
    PROM: quality of life week 24, 48 and 96
    PROM: (work) disability week 24, 48 and 96
    PROM: tolerability of treatment week 24, 48 and 96
    E.5.2.1Timepoint(s) of evaluation of this end point
    see E.5.2.
    Zie E 5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Standaard Step-up behandeling
    Standard Step-up treatment
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Laatste visite van Laatste deelnemer
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 146
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state146
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    geen
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-08-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2023 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA